5.5.1 COVID-19

Nirmatrelvir plus Ritonavir, Sotrovimab, Tocilizumab (use of tocilizumab biosimilar -Tyenne® is also recommended)	These High-Cost Drugs has been approved for the following indications: - for treatment of COVID-19 as per NICE Guidance
	NOT recommended by NICE. (Casirivimab plus imdevimab (Ronapreve, Roche Products) is NOT recommended by NICE.)
For more information and NICE Guidance Click Here	Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 NICE Guidance TA878
Remdesivir ICB commissioned - approval via Blueteq	This High-Cost Drug has been approved for the following indications: - for treatment of COVID-19 as per NICE GuidanceTA971 (Remdesivir is only recommended if the company provides it according to the commercial arrangement.)
For more information and NICE Guidance Click Here	Tixagevimab plus cilgavimab is not* recommended by NICE*